Mereo Biopharma Group is a biopharmaceutical company focused on the development and commercialization of therapeutics. Co.'s portfolio consists of six clinical-stage product candidates. Co. is developing Setrusumab (BPS-804) for the treatment of osteogenesis imperfecta, Alvelestat (MPH-966) for the treatment of severe alpha-1 antitrypsin deficiency, Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease, and Leflutrozole (BGS-649) for the treatment of hypogonadotropic hypogonadism, in obese men. Co.'s two oncology anti-cancer therapeutic candidates include Etigilimab (OMP-313M32) and Navicixizumab (OMP-305B83). The MREO stock yearly return is shown above.
The yearly return on the MREO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MREO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|